argenx reports full year 2019 financial results and provides fourth quarter business update
February 27, 2020 01:00 ET
|
argenx SE
Topline data from Phase 3 ADAPT trial of efgartigimod in gMG expected in mid-2020Continued progress across broadest FcRn antagonist pipeline with up to five Phase 3 trials to be...
argenx announces closing of global offering
November 12, 2019 16:00 ET
|
argenx SE
Regulated information – Inside information November 12, 2019 - 10:00 PM CET Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company...
argenx announces full exercise of underwriters’ option to purchase additional ADSs
November 08, 2019 01:00 ET
|
argenx SE
Regulated information – Inside information November 8, 2019, 7:00 AM CET Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company...
argenx raises $484 million in gross proceeds in a global offering
November 06, 2019 22:45 ET
|
argenx SE
Regulated information – Inside information November 6, 2019, 10:45 PM ESTNovember 7, 2019, 04:45 AM CET Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a...
argenx reports third quarter 2019 financial results and provides business update
October 24, 2019 01:00 ET
|
argenx SE
Enrollment on track for Phase 3 ADAPT trial of efgartigimod in gMG patients with topline results expected in 2H20Two efgartigimod trial initiations expected in 4Q19: Phase 2 proof-of-concept...
argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference
September 03, 2019 01:00 ET
|
argenx SE
September 3, 2019 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based...
argenx to Present at 2019 Wedbush PacGrow Healthcare Conference
August 06, 2019 01:00 ET
|
argenx SE
August 6, 2019 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based...
argenx reports half year 2019 financial results and second quarter business update
August 01, 2019 01:00 ET
|
argenx SE
Enrollment on track for Phase 3 ADAPT trial of efgartigimod (ARGX-113) in generalized myasthenia gravis (gMG) patients with topline results expected in 2H20First of two registration trials from...
argenx to report half year 2019 financial results and second quarter business update on August 1, 2019
July 25, 2019 01:00 ET
|
argenx SE
July 25, 2019 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based...
argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day
May 22, 2019 01:00 ET
|
argenx SE
Expands pipeline with ARGX-117 and ARGX-118; two new pipeline candidates from its Innovative Access Program addressing first-in-class targetsHighlights formation of two global therapeutic...